CASTLE BIOSCIENCES INC (CSTL) Stock Fundamental Analysis
USA - NASDAQ:CSTL - US14843C1053 - Common Stock
34.74 USD
+1.7 (+5.15%)
34.84 USD
+0.1 (+0.29%)
Taking everything into account, CSTL scores 4 out of 10 in our fundamental rating. CSTL was compared to 100 industry peers in the Health Care Providers & Services industry. CSTL has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CSTL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CSTL was profitable.
In the past year CSTL had a positive cash flow from operations.
In the past 5 years CSTL reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CSTL reported negative operating cash flow in multiple years.
1.2 Ratios
CSTL's Return On Assets of -2.17% is on the low side compared to the rest of the industry. CSTL is outperformed by 60.00% of its industry peers.
CSTL has a Return On Equity of -2.62%. This is comparable to the rest of the industry: CSTL outperforms 49.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSTL's Profit Margin has been stable in the last couple of years.
In the last couple of years the Operating Margin of CSTL has declined.
Looking at the Gross Margin, with a value of 79.94%, CSTL belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CSTL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CSTL has been increased compared to 5 years ago.
The debt/assets ratio for CSTL is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.81 indicates that CSTL is not in any danger for bankruptcy at the moment.
CSTL's Altman-Z score of 6.81 is amongst the best of the industry. CSTL outperforms 90.00% of its industry peers.
CSTL has a debt to FCF ratio of 0.41. This is a very positive value and a sign of high solvency as it would only need 0.41 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.41, CSTL belongs to the best of the industry, outperforming 94.00% of the companies in the same industry.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CSTL has a better Debt to Equity ratio (0.02) than 83.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Altman-Z | 6.81 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
A Current Ratio of 6.47 indicates that CSTL has no problem at all paying its short term obligations.
The Current ratio of CSTL (6.47) is better than 96.00% of its industry peers.
CSTL has a Quick Ratio of 6.31. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CSTL (6.31) is better than 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 |
3. Growth
3.1 Past
CSTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
The Earnings Per Share has been growing by 29.69% on average over the past years. This is a very strong growth
CSTL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.15%.
CSTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.95% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
3.2 Future
The Earnings Per Share is expected to decrease by -23.65% on average over the next years. This is quite bad
CSTL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.62% yearly.
EPS Next Y-393.05%
EPS Next 2Y-122.91%
EPS Next 3Y-70.43%
EPS Next 5Y-23.65%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.62%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 133.62, which means the current valuation is very expensive for CSTL.
CSTL's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 26.28. CSTL is valued rather expensively when compared to this.
The Forward Price/Earnings Ratio is negative for CSTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 133.62 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSTL is valued a bit more expensive than 62.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSTL is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.71 | ||
| EV/EBITDA | 67.53 |
4.3 Compensation for Growth
CSTL's earnings are expected to decrease with -70.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)4.5
EPS Next 2Y-122.91%
EPS Next 3Y-70.43%
5. Dividend
5.1 Amount
CSTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
34.74
+1.7 (+5.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners93.13%
Inst Owner Change-0.21%
Ins Owners2.7%
Ins Owner Change1.33%
Market Cap1.01B
Revenue(TTM)343.53M
Net Income(TTM)-12.24M
Analysts88.57
Price Target36.34 (4.61%)
Short Float %5.71%
Short Ratio4.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.17%
Min EPS beat(2)96.25%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)151.85%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)149.84%
EPS beat(12)10
Avg EPS beat(12)106.51%
EPS beat(16)13
Avg EPS beat(16)87.37%
Revenue beat(2)2
Avg Revenue beat(2)16.33%
Min Revenue beat(2)14.33%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)10.84%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)11.87%
Revenue beat(12)12
Avg Revenue beat(12)11.82%
Revenue beat(16)16
Avg Revenue beat(16)10.9%
PT rev (1m)0%
PT rev (3m)-1.35%
EPS NQ rev (1m)0.95%
EPS NQ rev (3m)21.36%
EPS NY rev (1m)0.86%
EPS NY rev (3m)24.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 133.62 | ||
| Fwd PE | N/A | ||
| P/S | 2.93 | ||
| P/FCF | 39.71 | ||
| P/OCF | 16.31 | ||
| P/B | 2.16 | ||
| P/tB | 2.76 | ||
| EV/EBITDA | 67.53 |
EPS(TTM)0.26
EY0.75%
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)0.87
FCFY2.52%
OCF(TTM)2.13
OCFY6.13%
SpS11.84
BVpS16.1
TBVpS12.59
PEG (NY)N/A
PEG (5Y)4.5
Graham Number9.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% | ||
| FCFM | 7.39% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 85.13% | ||
| Cap/Sales | 10.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 789.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 | ||
| Altman-Z | 6.81 |
F-Score4
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
EPS Next Y-393.05%
EPS Next 2Y-122.91%
EPS Next 3Y-70.43%
EPS Next 5Y-23.65%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.62%
EBIT growth 1Y-3265.41%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year330.52%
EBIT Next 3Y-140.1%
EBIT Next 5Y-26.67%
FCF growth 1Y160.68%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y304.51%
OCF growth 3YN/A
OCF growth 5Y56%
CASTLE BIOSCIENCES INC / CSTL FAQ
What is the fundamental rating for CSTL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CSTL.
What is the valuation status for CSTL stock?
ChartMill assigns a valuation rating of 1 / 10 to CASTLE BIOSCIENCES INC (CSTL). This can be considered as Overvalued.
Can you provide the profitability details for CASTLE BIOSCIENCES INC?
CASTLE BIOSCIENCES INC (CSTL) has a profitability rating of 2 / 10.
What is the valuation of CASTLE BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CASTLE BIOSCIENCES INC (CSTL) is 133.62 and the Price/Book (PB) ratio is 2.16.
How financially healthy is CASTLE BIOSCIENCES INC?
The financial health rating of CASTLE BIOSCIENCES INC (CSTL) is 8 / 10.